Last reviewed · How we verify
Eflornithine plus Sulindac
Eflornithine plus Sulindac is a Polyamine synthesis inhibitor + NSAID combination Small molecule drug developed by Cancer Prevention Pharmaceuticals, Inc.. It is currently in Phase 3 development for Colorectal cancer prevention in high-risk populations. Also known as: DFMO.
Eflornithine inhibits polyamine synthesis while sulindac acts as a non-selective NSAID to reduce inflammation and promote apoptosis, together targeting colorectal cancer prevention.
Eflornithine inhibits polyamine synthesis while sulindac acts as a non-selective NSAID to reduce inflammation and promote apoptosis, together targeting colorectal cancer prevention. Used for Colorectal cancer prevention in high-risk populations.
At a glance
| Generic name | Eflornithine plus Sulindac |
|---|---|
| Also known as | DFMO |
| Sponsor | Cancer Prevention Pharmaceuticals, Inc. |
| Drug class | Polyamine synthesis inhibitor + NSAID combination |
| Target | Ornithine decarboxylase (ODC); COX-1/COX-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis that is often elevated in cancer cells. Sulindac is a non-selective cyclooxygenase (COX) inhibitor with anti-inflammatory and pro-apoptotic properties. The combination is designed to synergistically reduce colorectal polyp formation and cancer risk by depleting polyamines and suppressing COX-mediated proliferative signaling.
Approved indications
- Colorectal cancer prevention in high-risk populations
Common side effects
- Gastrointestinal disturbances
- Hearing loss (eflornithine-associated)
- Diarrhea
- Abdominal pain
Key clinical trials
- S0820, Adenoma and Second Primary Prevention Trial (PHASE3)
- Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) (PHASE3)
- A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) (PHASE3)
- Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps (PHASE3)
- Urinary Biomarker Study With Sulindac and Difluoromethylornithine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eflornithine plus Sulindac CI brief — competitive landscape report
- Eflornithine plus Sulindac updates RSS · CI watch RSS
- Cancer Prevention Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Eflornithine plus Sulindac
What is Eflornithine plus Sulindac?
How does Eflornithine plus Sulindac work?
What is Eflornithine plus Sulindac used for?
Who makes Eflornithine plus Sulindac?
Is Eflornithine plus Sulindac also known as anything else?
What drug class is Eflornithine plus Sulindac in?
What development phase is Eflornithine plus Sulindac in?
What are the side effects of Eflornithine plus Sulindac?
What does Eflornithine plus Sulindac target?
Related
- Drug class: All Polyamine synthesis inhibitor + NSAID combination drugs
- Target: All drugs targeting Ornithine decarboxylase (ODC); COX-1/COX-2
- Manufacturer: Cancer Prevention Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Colorectal cancer prevention in high-risk populations
- Also known as: DFMO
- Compare: Eflornithine plus Sulindac vs similar drugs
- Pricing: Eflornithine plus Sulindac cost, discount & access